Replimune Group (NASDAQ:REPL) Shares Up 6.7% - Here's Why

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares were up 6.7% during trading on Monday . The stock traded as high as $8.16 and last traded at $8.53. Approximately 41,152 shares were traded during trading, a decline of 95% from the average daily volume of 863,411 shares. The stock had previously closed at $8.00.

Analyst Ratings Changes

Several research firms have commented on REPL. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright raised their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $19.43.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm has a 50 day moving average price of $10.34 and a two-hundred day moving average price of $11.68. The company has a market capitalization of $674.19 million, a P/E ratio of -2.83 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd grew its position in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Replimune Group during the 4th quarter valued at $117,000. Finally, Quantinno Capital Management LP bought a new position in Replimune Group in the 4th quarter valued at $127,000. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.